COVID blood clot prevention drug safety checked in real hospital setting
NCT ID NCT07134738
Summary
This study looked at how safe and well-tolerated the medication Dimolegin® is when used to prevent blood clots in hospitalized adults with moderate COVID-19. Researchers observed 184 patients in real hospital settings who were already prescribed this medication as part of their standard care. The main goal was to track any bleeding events or side effects while patients took the drug once daily.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for COVID-19 are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Infectious Diseases Clinical Hospital No. 1
Moscow, Russia
-
Infectious Diseases Hospital No. 2
Sochi, Russia
-
Regional Clinical Hospital No. 3
Chelyabinsk, Russia
-
Regional Infectious Diseases Clinical Hospital
Yaroslavl, Russia
-
Republican Clinical Hospital named after Professor A.F. Agafonov
Kazan', Russia
-
Tomsk Regional Hospital
Tomsk, Russia
Conditions
Explore the condition pages connected to this study.